As the genetic abnormalities responsible for craniopharyngioma have been revealed, craniopharyngioma has been identified as an acquired tumor based on somatic mutations (β-catenin and BRAF) in recent years [1-2]. This tumor is histologically benign, and its overall annual incidence is 1.3 per one million people. The gene discussed is BRAF; the disease is neoplasm.